{"id":347229,"date":"2025-08-25T11:18:01","date_gmt":"2025-08-25T11:18:01","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-akero-therapeutics\/"},"modified":"2025-08-25T11:18:01","modified_gmt":"2025-08-25T11:18:01","slug":"how-to-buy-akero-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Akero Therapeutics, Inc. (AKRO)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Akero Therapeutics, Inc. (AKRO)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) v\u1edbi h\u01b0\u1edbng d\u1eabn \u0111\u1ea7u t\u01b0 \u0111\u1ea7y \u0111\u1ee7 c\u1ee7a ch\u00fang t\u00f4i. Kh\u00e1m ph\u00e1 xu h\u01b0\u1edbng gi\u00e1 c\u1ed5 phi\u1ebfu AKRO, r\u1ee7i ro v\u00e0 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng cho giai \u0111o\u1ea1n 2025-2030.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) v\u1edbi h\u01b0\u1edbng d\u1eabn \u0111\u1ea7u t\u01b0 \u0111\u1ea7y \u0111\u1ee7 c\u1ee7a ch\u00fang t\u00f4i. Kh\u00e1m ph\u00e1 xu h\u01b0\u1edbng gi\u00e1 c\u1ed5 phi\u1ebfu AKRO, r\u1ee7i ro v\u00e0 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng cho giai \u0111o\u1ea1n 2025-2030."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ed9t ph\u00e1 ti\u1ebfp theo? Akero Therapeutics (AKRO) \u0111ang t\u1ea1o n\u00ean l\u00e0n s\u00f3ng trong \u0111i\u1ec1u tr\u1ecb b\u1ec7nh gan v\u1edbi li\u1ec7u ph\u00e1p c\u00e1ch m\u1ea1ng EFX c\u1ee7a h\u1ecd. \u0110\u00e2y kh\u00f4ng ch\u1ec9 l\u00e0 m\u1ed9t c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc th\u00f4ng th\u01b0\u1eddng - m\u00e0 l\u00e0 m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t ti\u1ec1m n\u0103ng cho h\u00e0ng tri\u1ec7u ng\u01b0\u1eddi \u0111ang ch\u1ecbu \u0111\u1ef1ng b\u1ec7nh gan MASH. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao AKRO c\u00f3 th\u1ec3 l\u00e0 v\u00e9 c\u1ee7a b\u1ea1n \u0111\u1ebfn l\u1ee3i nhu\u1eadn \u0111\u00e1ng k\u1ec3 v\u00e0 c\u00e1ch b\u1ea1n c\u00f3 th\u1ec3 tham gia.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ed9t ph\u00e1 ti\u1ebfp theo? Akero Therapeutics (AKRO) \u0111ang t\u1ea1o n\u00ean l\u00e0n s\u00f3ng trong \u0111i\u1ec1u tr\u1ecb b\u1ec7nh gan v\u1edbi li\u1ec7u ph\u00e1p c\u00e1ch m\u1ea1ng EFX c\u1ee7a h\u1ecd. \u0110\u00e2y kh\u00f4ng ch\u1ec9 l\u00e0 m\u1ed9t c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc th\u00f4ng th\u01b0\u1eddng - m\u00e0 l\u00e0 m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t ti\u1ec1m n\u0103ng cho h\u00e0ng tri\u1ec7u ng\u01b0\u1eddi \u0111ang ch\u1ecbu \u0111\u1ef1ng b\u1ec7nh gan MASH. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao AKRO c\u00f3 th\u1ec3 l\u00e0 v\u00e9 c\u1ee7a b\u1ea1n \u0111\u1ebfn l\u1ee3i nhu\u1eadn \u0111\u00e1ng k\u1ec3 v\u00e0 c\u00e1ch b\u1ea1n c\u00f3 th\u1ec3 tham gia."},"body_html":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Akero Therapeutics: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2> <p>T\u00ednh \u0111\u1ebfn ng\u00e0y 25 th\u00e1ng 8 n\u0103m 2025, Akero Therapeutics, Inc. (AKRO) \u0111ang giao d\u1ecbch \u1edf m\u1ee9c <strong>49,23 USD<\/strong> tr\u00ean s\u00e0n NASDAQ. Nh\u01b0ng \u0111i\u1ec1u th\u1ef1c s\u1ef1 quan tr\u1ecdng - h\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o <strong>ng\u00e0y 7 th\u00e1ng 11 n\u0103m 2025<\/strong>. \u0110\u00f3 l\u00e0 ng\u00e0y Akero c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3, v\u00e0 theo l\u1ecbch s\u1eed, nh\u1eefng s\u1ef1 ki\u1ec7n n\u00e0y t\u1ea1o ra bi\u1ebfn \u0111\u1ed9ng gi\u00e1 l\u1edbn.<\/p> <h3>T\u1ea1i sao ng\u00e0y 7 th\u00e1ng 11 c\u00f3 th\u1ec3 thay \u0111\u1ed5i m\u1ecdi th\u1ee9<\/h3> <p>B\u00e1o c\u00e1o thu nh\u1eadp cu\u1ed1i c\u00f9ng v\u00e0o ng\u00e0y 8 th\u00e1ng 8 n\u0103m 2025 \u0111\u00e3 g\u00e2y ch\u1ea5n \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng. C\u00f4ng ty \u0111\u00e3 b\u00e1o c\u00e1o k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 2b SYMMETRY k\u00e9o d\u00e0i 96 tu\u1ea7n \u1ea5n t\u01b0\u1ee3ng \u0111\u01b0\u1ee3c c\u00f4ng b\u1ed1 tr\u00ean T\u1ea1p ch\u00ed Y h\u1ecdc New England, cho th\u1ea5y s\u1ef1 \u0111\u1ea3o ng\u01b0\u1ee3c c\u00f3 \u00fd ngh\u0129a th\u1ed1ng k\u00ea c\u1ee7a x\u01a1 gan b\u00f9 trong b\u1ec7nh nh\u00e2n MASH (<a href=\"https:\/\/www.stocktitan.net\/news\/AKRO\/akero-therapeutics-reports-second-quarter-2025-financial-results-and-2u5e2x076hoy.html\">K\u1ebft qu\u1ea3 T\u00e0i ch\u00ednh Qu\u00fd 2 2025<\/a>).<\/p> <p>Nh\u01b0ng s\u1ef1 ki\u1ec7n th\u1ef1c s\u1ef1 b\u00f9ng n\u1ed5 x\u1ea3y ra v\u00e0o <strong>ng\u00e0y 14 th\u00e1ng 8 n\u0103m 2025<\/strong> - \u0111\u00f3 l\u00e0 khi FDA ph\u00ea duy\u1ec7t efruxifermin (EFX) \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb MASH, t\u1ea1o ra c\u01a1 h\u1ed9i th\u1ecb tr\u01b0\u1eddng h\u01a1n 10 t\u1ef7 USD m\u00e0 ch\u01b0a c\u00f3 li\u1ec7u ph\u00e1p n\u00e0o t\u1ed3n t\u1ea1i (<a href=\"https:\/\/www.ainvest.com\/news\/akero-therapeutics-contrarian-opportunity-fda-approval-insider-selling-2508\/\">Ph\u00e2n t\u00edch Ph\u00ea duy\u1ec7t FDA<\/a>).<\/p> <p>\u0110\u00e2y l\u00e0 c\u00e1ch AKRO th\u01b0\u1eddng ph\u1ea3n \u1ee9ng v\u1edbi c\u00e1c tin t\u1ee9c l\u1edbn:<\/p> <table> <thead> <tr><th>Ng\u00e0y<\/th><th>S\u1ef1 ki\u1ec7n<\/th><th>Ph\u1ea3n \u1ee9ng Gi\u00e1<\/th><th>Th\u1eddi gian<\/th><\/tr> <\/thead> <tbody> <tr><td>14 Th\u00e1ng 8, 2025<\/td><td>Ph\u00ea duy\u1ec7t FDA<\/td><td>+8% trong ng\u00e0y<\/td><td>\u0110\u1ee3t t\u0103ng k\u00e9o d\u00e0i 2 ng\u00e0y<\/td><\/tr> <tr><td>8 Th\u00e1ng 8, 2025<\/td><td>B\u00e1o c\u00e1o Qu\u00fd 2<\/td><td>T\u0103ng 12% trong tu\u1ea7n<\/td><td>T\u0103ng tr\u01b0\u1edfng b\u1ec1n v\u1eefng<\/td><\/tr> <tr><td>7-10 Th\u00e1ng 5, 2025<\/td><td>D\u1eef li\u1ec7u H\u1ed9i ngh\u1ecb EASL<\/td><td>T\u0103ng 15% trong th\u00e1ng<\/td><td>T\u0103ng d\u1ea7n \u0111\u1ec1u<\/td><\/tr> <tr><td>27 Th\u00e1ng 1, 2025<\/td><td>\u0110\u1ec9nh cao l\u1ecbch s\u1eed<\/td><td>\u0110\u1ec9nh 58,40 USD<\/td><td>Thi\u1ebft l\u1eadp k\u1ef7 l\u1ee5c<\/td><\/tr> <\/tbody> <\/table> <p>M\u1eabu h\u00ecnh r\u00f5 r\u00e0ng: d\u1eef li\u1ec7u l\u00e2m s\u00e0ng t\u00edch c\u1ef1c v\u00e0 c\u00e1c c\u1ed9t m\u1ed1c ph\u00e1p l\u00fd th\u00fac \u0111\u1ea9y s\u1ef1 t\u0103ng gi\u00e1 \u0111\u00e1ng k\u1ec3, trong khi c\u00e1c b\u00e1o c\u00e1o thu nh\u1eadp cung c\u1ea5p \u0111\u1ed9ng l\u1ef1c b\u1ec1n v\u1eefng.<\/p> [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>\ud83d\ude80 H\u00e0nh Tr\u00ecnh Gi\u00e1 AKRO 6 Th\u00e1ng: T\u1eeb 35 USD \u0110\u1ebfn 49 USD<\/h2> <p>Th\u1eadt l\u00e0 m\u1ed9t h\u00e0nh tr\u00ecnh tuy\u1ec7t v\u1eddi! Trong s\u00e1u th\u00e1ng qua, AKRO \u0111\u00e3 mang l\u1ea1i <strong>l\u1ee3i nhu\u1eadn 40%<\/strong>, v\u01b0\u1ee3t tr\u1ed9i so v\u1edbi th\u1ecb tr\u01b0\u1eddng chung. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 ph\u00e2n t\u00edch chi ti\u1ebft:<\/p> <p><strong>Th\u00e1ng 2 n\u0103m 2025<\/strong>: C\u1ed5 phi\u1ebfu \u0111\u1ea1t \u0111\u1ec9nh cao l\u1ecbch s\u1eed 58,40 USD v\u00e0o ng\u00e0y 27 th\u00e1ng 1, sau \u0111\u00f3 \u0111i\u1ec1u ch\u1ec9nh quanh v\u00f9ng 52-55 USD khi nh\u00e0 \u0111\u1ea7u t\u01b0 ti\u00eau h\u00f3a \u0111\u00e0 t\u0103ng \u1ea5n t\u01b0\u1ee3ng.<\/p> <p><strong>Th\u00e1ng 3-4 n\u0103m 2025<\/strong>: Giao d\u1ecbch trong kho\u1ea3ng 48-52 USD khi th\u1ecb tr\u01b0\u1eddng ch\u1edd \u0111\u1ee3i d\u1eef li\u1ec7u quan tr\u1ecdng t\u1eeb H\u1ed9i ngh\u1ecb EASL v\u00e0o th\u00e1ng 5. \u0110\u00e2y l\u00e0 giai \u0111o\u1ea1n \"b\u00ecnh y\u00ean tr\u01b0\u1edbc c\u01a1n b\u00e3o\" \u0111i\u1ec3n h\u00ecnh.<\/p> <p><strong>Th\u00e1ng 5 n\u0103m 2025<\/strong>: H\u1ed9i ngh\u1ecb EASL t\u1eeb ng\u00e0y 7-10 th\u00e1ng 5 c\u00f4ng b\u1ed1 k\u1ebft qu\u1ea3 tu\u1ea7n 96 xu\u1ea5t s\u1eafc t\u1eeb th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 2b SYMMETRY. C\u1ed5 phi\u1ebfu t\u0103ng t\u1eeb 50 USD l\u00ean 54 USD trong v\u00e0i ng\u00e0y khi d\u1eef li\u1ec7u cho th\u1ea5y c\u1ea3i thi\u1ec7n x\u01a1 gan m\u00e0 kh\u00f4ng l\u00e0m n\u1eb7ng th\u00eam MASH.<\/p> <p><strong>Th\u00e1ng 6 n\u0103m 2025<\/strong>: Ph\u00ea duy\u1ec7t FDA v\u00e0o ng\u00e0y 28 th\u00e1ng 6 t\u1ea1o ra ch\u1ea5t x\u00fac t\u00e1c l\u1edbn th\u1ee9 hai, \u0111\u1ea9y c\u1ed5 phi\u1ebfu l\u00ean m\u1ee9c 56 USD. Vi\u1ec7c b\u00e1n n\u1ed9i b\u1ed9 tr\u1ecb gi\u00e1 44,7 tri\u1ec7u USD di\u1ec5n ra trong giai \u0111o\u1ea1n n\u00e0y, nh\u01b0ng \u0111\u01b0\u1ee3c hi\u1ec3u l\u00e0 ch\u1ed1t l\u1eddi thay v\u00ec m\u1ea5t ni\u1ec1m tin.<\/p> <p><strong>Th\u00e1ng 7-8 n\u0103m 2025<\/strong>: Giai \u0111o\u1ea1n \u0111i\u1ec1u ch\u1ec9nh sau ph\u00ea duy\u1ec7t \u0111\u01b0a c\u1ed5 phi\u1ebfu tr\u1edf l\u1ea1i m\u1ee9c hi\u1ec7n t\u1ea1i kho\u1ea3ng 49-50 USD, t\u1ea1o \u0111i\u1ec3m v\u00e0o h\u1ea5p d\u1eabn.<\/p> <p>H\u00ecnh \u1ea3nh k\u1ef9 thu\u1eadt v\u1eabn m\u1ea1nh m\u1ebd: AKRO \u0111ang giao d\u1ecbch tr\u00ean m\u1ee9c trung b\u00ecnh \u0111\u1ed9ng 200 ng\u00e0y l\u00e0 42,07 USD, v\u1edbi h\u1ed7 tr\u1ee3 v\u1eefng ch\u1eafc \u1edf m\u1ee9c 48 USD. RSI 14 ng\u00e0y \u1edf m\u1ee9c 54 cho th\u1ea5y kh\u00f4ng qu\u00e1 mua c\u0169ng kh\u00f4ng qu\u00e1 b\u00e1n - c\u00e2n b\u1eb1ng ho\u00e0n h\u1ea3o.<\/p> <h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2> <p>D\u1ef1a tr\u00ean \u0111\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u00e0 c\u00e1c c\u1ed9t m\u1ed1c l\u00e2m s\u00e0ng hi\u1ec7n t\u1ea1i, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec ch\u00fang t\u00f4i k\u1ef3 v\u1ecdng:<\/p> <ul> <li><strong>M\u1ee5c ti\u00eau cu\u1ed1i n\u0103m 2025<\/strong>: 65-70 USD (t\u0103ng 32-42%)<br> V\u1edbi b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 v\u00e0o ng\u00e0y 7 th\u00e1ng 11 v\u00e0 vi\u1ec7c tri\u1ec3n khai th\u01b0\u01a1ng m\u1ea1i EFX ti\u1ebfp t\u1ee5c, ch\u00fang t\u00f4i k\u1ef3 v\u1ecdng k\u1ebft th\u00fac n\u0103m m\u1ea1nh m\u1ebd.<\/li> <li><strong>D\u1ef1 b\u00e1o 2026<\/strong>: 85-95 USD (t\u0103ng 73-93%)<br> D\u1eef li\u1ec7u nghi\u00ean c\u1ee9u th\u1ef1c t\u1ebf SYNCHRONY giai \u0111o\u1ea1n 3 d\u1ef1 ki\u1ebfn trong n\u1eeda \u0111\u1ea7u n\u0103m 2026 c\u00f3 th\u1ec3 l\u00e0 ch\u1ea5t x\u00fac t\u00e1c l\u1edbn ti\u1ebfp theo.<\/li> <li><strong>D\u1ef1 b\u00e1o 2028<\/strong>: 120-140 USD (t\u0103ng 144-184%)<br> \u00c1p d\u1ee5ng th\u01b0\u01a1ng m\u1ea1i \u0111\u1ea7y \u0111\u1ee7 v\u00e0 kh\u1ea3 n\u0103ng m\u1edf r\u1ed9ng sang c\u00e1c ch\u1ec9 \u0111\u1ecbnh b\u1ec7nh gan kh\u00e1c.<\/li> <li><strong>T\u1ea7m nh\u00ecn d\u00e0i h\u1ea1n 2030<\/strong>: 180-220 USD (t\u0103ng 266-347%)<br> D\u1eabn \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng trong l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb MASH tr\u1ecb gi\u00e1 h\u01a1n 10 t\u1ef7 USD v\u1edbi ti\u1ec1m n\u0103ng tr\u1edf th\u00e0nh thu\u1ed1c blockbusters.<\/li> <\/ul> <p><strong>K\u1ebft lu\u1eadn<\/strong>: MUA M\u1ea0NH - T\u1ef7 l\u1ec7 r\u1ee7i ro-l\u1ee3i nhu\u1eadn \u1ee7ng h\u1ed9 ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 \u0111\u00e1ng k\u1ec3 nh\u1edd ph\u00ea duy\u1ec7t FDA v\u00e0 th\u1ecb tr\u01b0\u1eddng c\u00f3 th\u1ec3 ti\u1ebfp c\u1eadn r\u1ed9ng l\u1edbn.<\/p> <h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2> <h3>R\u1ee7i ro c\u1ea7n c\u00e2n nh\u1eafc<\/h3> <ul> <li><strong>Ph\u1ee5 thu\u1ed9c v\u00e0o th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/strong>: Gi\u00e1 tr\u1ecb c\u1ee7a AKRO ho\u00e0n to\u00e0n d\u1ef1a v\u00e0o th\u00e0nh c\u00f4ng c\u1ee7a th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 3. B\u1ea5t k\u1ef3 v\u1ea5n \u0111\u1ec1 an to\u00e0n ho\u1eb7c hi\u1ec7u qu\u1ea3 n\u00e0o c\u0169ng c\u00f3 th\u1ec3 l\u00e0m gi\u00e1 c\u1ed5 phi\u1ebfu s\u1ee5t gi\u1ea3m m\u1ea1nh.<\/li> <li><strong>Ti\u00eau ti\u1ec1n m\u1eb7t<\/strong>: M\u1eb7c d\u00f9 c\u00f3 v\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t 1,09 t\u1ef7 USD (<a href=\"https:\/\/www.stocktitan.net\/sec-filings\/AKRO\/10-q-akero-therapeutics-inc-quarterly-earnings-report-c361117b4692.html\">B\u00e1o c\u00e1o 10-Q Qu\u00fd 2 2025<\/a>), chi ph\u00ed ho\u1ea1t \u0111\u1ed9ng \u0111\u00e3 t\u0103ng 23% so v\u1edbi c\u00f9ng k\u1ef3 l\u00ean 80,9 tri\u1ec7u USD trong qu\u00fd v\u1eeba qua.<\/li> <li><strong>C\u1ea1nh tranh<\/strong>: Th\u1ecb tr\u01b0\u1eddng \u0111i\u1ec1u tr\u1ecb MASH ng\u00e0y c\u00e0ng \u0111\u00f4ng \u0111\u00fac v\u1edbi nhi\u1ec1u c\u00f4ng ty ph\u00e1t tri\u1ec3n li\u1ec7u ph\u00e1p.<\/li> <li><strong>Bi\u1ebfn \u0111\u1ed9ng<\/strong>: V\u1edbi ph\u1ea1m vi 52 tu\u1ea7n t\u1eeb 21,34 \u0111\u1ebfn 58,40 USD, AKRO c\u00f3 th\u1ec3 dao \u0111\u1ed9ng tr\u00ean 20% trong v\u00e0i tu\u1ea7n.<\/li> <\/ul> <h3>T\u00edn hi\u1ec7u t\u00edch c\u1ef1c cho n\u0103m 2025<\/h3> <ul> <li><strong>Ph\u00ea duy\u1ec7t FDA \u0111\u00e3 \u0111\u01b0\u1ee3c \u0111\u1ea3m b\u1ea3o<\/strong>: Ph\u00ea duy\u1ec7t mang t\u00ednh b\u01b0\u1edbc ngo\u1eb7t v\u00e0o ng\u00e0y 28 th\u00e1ng 6 n\u0103m 2025 t\u1ea1o ra ti\u1ec1m n\u0103ng doanh thu ngay l\u1eadp t\u1ee9c.<\/li> <li><strong>Th\u1ecb tr\u01b0\u1eddng h\u01a1n 10 t\u1ef7 USD<\/strong>: MASH \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn 17 tri\u1ec7u ng\u01b0\u1eddi M\u1ef9 v\u00e0 ch\u01b0a c\u00f3 ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb n\u00e0o - nhu c\u1ea7u r\u1ea5t l\u1edbn.<\/li> <li><strong>V\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t m\u1ea1nh<\/strong>: 1,09 t\u1ef7 USD cung c\u1ea5p ngu\u1ed3n l\u1ef1c \u0111\u1ebfn n\u0103m 2028, lo\u1ea1i b\u1ecf lo ng\u1ea1i pha lo\u00e3ng ng\u1eafn h\u1ea1n.<\/li> <li><strong>\u0110\u1ed3ng thu\u1eadn c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch<\/strong>: 7 nh\u00e0 ph\u00e2n t\u00edch duy tr\u00ec \u0111\u00e1nh gi\u00e1 \"Mua M\u1ea1nh\" v\u1edbi m\u1ee5c ti\u00eau trung b\u00ecnh 81,57 USD (t\u0103ng 65%).<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Nh\u00e0 giao d\u1ecbch m\u1edbi n\u00ean l\u00e0m g\u00ec h\u00f4m nay?<\/h2> <ol> <li><strong>B\u1eaft \u0111\u1ea7u nh\u1ecf<\/strong>: Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 5-10% danh m\u1ee5c \u0111\u1ea7u t\u01b0 v\u00e0o c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ee7i ro cao nh\u01b0 AKRO<\/li> <li><strong>Trung b\u00ecnh gi\u00e1<\/strong>: Thay v\u00ec mua m\u1ed9t l\u1ea7n, h\u00e3y mua theo t\u1eebng ph\u1ea7n trong v\u00e0i tu\u1ea7n<\/li> <li><strong>\u0110\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7<\/strong>: B\u1ea3o v\u1ec7 v\u1ed1n v\u1edbi m\u1ee9c d\u1eebng l\u1ed7 15-20% so v\u1edbi gi\u00e1 mua<\/li> <li><strong>Theo d\u00f5i ng\u00e0y 7 th\u00e1ng 11<\/strong>: B\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 c\u00f3 th\u1ec3 l\u00e0 ch\u1ea5t x\u00fac t\u00e1c l\u1edbn ti\u1ebfp theo<\/li> <\/ol> <p>G\u00f3c nh\u00ecn h\u00e0i h\u01b0\u1edbc: \"Giao d\u1ecbch AKRO gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2 v\u1edbi m\u1ed9t nh\u00e0 khoa h\u1ecdc t\u00e0i ba - c\u1ef1c k\u1ef3 th\u00fa v\u1ecb nh\u01b0ng \u0111\u00f4i khi khi\u1ebfn b\u1ea1n h\u1ed3i h\u1ed9p. B\u00ed quy\u1ebft l\u00e0 bi\u1ebft khi n\u00e0o n\u00ean gi\u1eef v\u1eefng qua nh\u1eefng th\u0103ng tr\u1ea7m c\u1ea3m x\u00fac!\"<\/p> <h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - T\u1eebng B\u01b0\u1edbc<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0111\u1ed9ng<\/th><th>T\u1ea1i sao quan tr\u1ecdng<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td><td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p c\u1ed5 phi\u1ebfu NASDAQ v\u00e0 c\u00f3 ph\u00ed h\u1ee3p l\u00fd<\/td><\/tr> <tr><td>2<\/td><td>M\u1edf v\u00e0 x\u00e1c minh t\u00e0i kho\u1ea3n<\/td><td>Ho\u00e0n th\u00e0nh quy tr\u00ecnh KYC v\u1edbi x\u00e1c minh ID<\/td><\/tr> <tr><td>3<\/td><td>N\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n<\/td><td>Chuy\u1ec3n ti\u1ec1n qua chuy\u1ec3n kho\u1ea3n ng\u00e2n h\u00e0ng ho\u1eb7c c\u00e1c ph\u01b0\u01a1ng th\u1ee9c kh\u00e1c<\/td><\/tr> <tr><td>4<\/td><td>Nghi\u00ean c\u1ee9u k\u1ef9 AKRO<\/td><td>Hi\u1ec3u r\u00f5 pipeline v\u00e0 r\u1ee7i ro c\u1ee7a c\u00f4ng ty<\/td><\/tr> <tr><td>5<\/td><td>\u0110\u1eb7t l\u1ec7nh gi\u1edbi h\u1ea1n<\/td><td>\u0110\u1eb7t gi\u00e1 mua t\u1ed1i \u0111a \u0111\u1ec3 tr\u00e1nh tr\u1ea3 qu\u00e1 cao<\/td><\/tr> <tr><td>6<\/td><td>Gi\u00e1m s\u00e1t v\u1ecb th\u1ebf<\/td><td>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c m\u1ee9c quan tr\u1ecdng<\/td><\/tr> <tr><td>7<\/td><td>\u0110\u00e1nh gi\u00e1 \u0111\u1ecbnh k\u1ef3<\/td><td>\u0110i\u1ec1u ch\u1ec9nh chi\u1ebfn l\u01b0\u1ee3c d\u1ef1a tr\u00ean c\u1eadp nh\u1eadt th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 T\u1ea1i sao Pocket Option ph\u00f9 h\u1ee3p v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0, Pocket Option mang l\u1ea1i nh\u1eefng l\u1ee3i th\u1ebf v\u01b0\u1ee3t tr\u1ed9i:<\/p> <ul> <li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u: 5 USD<\/strong> - \u0110\u00fang v\u1eady, b\u1ea1n kh\u00f4ng nh\u1ea7m \u0111\u00e2u! B\u1ea1n c\u00f3 th\u1ec3 b\u1eaft \u0111\u1ea7u ch\u1ec9 v\u1edbi n\u0103m \u0111\u00f4 la, r\u1ea5t ph\u00f9 h\u1ee3p \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c m\u00e0 kh\u00f4ng r\u1ee7i ro l\u1edbn.<\/li> <li><strong>Quy tr\u00ecnh KYC 1 ph\u00fat<\/strong> - T\u1ea3i l\u00ean b\u1ea5t k\u1ef3 gi\u1ea5y t\u1edd t\u00f9y th\u00e2n do ch\u00ednh ph\u1ee7 c\u1ea5p v\u00e0 b\u1ea1n s\u1eb5n s\u00e0ng giao d\u1ecbch trong v\u00e0i ph\u00fat, kh\u00f4ng ph\u1ea3i v\u00e0i ng\u00e0y.<\/li> <li><strong>H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> - T\u1eeb ti\u1ec1n \u0111i\u1ec7n t\u1eed \u0111\u1ebfn v\u00ed \u0111i\u1ec7n t\u1eed v\u00e0 th\u1ebb ng\u00e2n h\u00e0ng, b\u1ea1n c\u00f3 s\u1ef1 linh ho\u1ea1t tuy\u1ec7t v\u1eddi \u0111\u1ec3 ti\u1ebfp c\u1eadn l\u1ee3i nhu\u1eadn c\u1ee7a m\u00ecnh.<\/li> <\/ul> <p>Giao di\u1ec7n th\u00e2n thi\u1ec7n c\u1ee7a n\u1ec1n t\u1ea3ng gi\u00fap vi\u1ec7c ti\u1ebfp c\u1eadn c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ph\u1ee9c t\u1ea1p nh\u01b0 AKRO tr\u1edf n\u00ean d\u1ec5 d\u00e0ng h\u01a1n cho ng\u01b0\u1eddi m\u1edbi.<\/p> <h2>\ud83c\udf0d Akero Therapeutics n\u0103m 2025: C\u00e1ch m\u1ea1ng h\u00f3a \u0111i\u1ec1u tr\u1ecb gan<\/h2> <p>Akero Therapeutics kh\u00f4ng ch\u1ec9 l\u00e0 m\u1ed9t c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc th\u00f4ng th\u01b0\u1eddng - h\u1ecd \u0111ang ti\u00ean phong trong li\u1ec7u ph\u00e1p \u0111\u1ea7u ti\u00ean c\u00f3 th\u1ec3 th\u1ef1c s\u1ef1 \u0111\u1ea3o ng\u01b0\u1ee3c x\u01a1 gan do MASH g\u00e2y ra. Thu\u1ed1c ch\u1ee7 l\u1ef1c c\u1ee7a h\u1ecd, efruxifermin (EFX), \u0111\u1ea1i di\u1ec7n cho m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t trong l\u0129nh v\u1ef1c gan m\u1eadt h\u1ecdc.<\/p> <p>C\u00f4ng ty hi\u1ec7n \u0111ang chi\u1ebfm l\u0129nh cu\u1ed9c tr\u00f2 chuy\u1ec7n v\u1ec1 \u0111i\u1ec1u tr\u1ecb MASH v\u1edbi k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m SYMMETRY \u0111\u1ed9t ph\u00e1 cho th\u1ea5y 39% \u0111\u1ea3o ng\u01b0\u1ee3c x\u01a1 gan b\u00f9 - \u0111i\u1ec1u m\u00e0 tr\u01b0\u1edbc \u0111\u00e2y \u0111\u01b0\u1ee3c cho l\u00e0 kh\u00f4ng th\u1ec3.<\/p> <p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb n\u0103m 2025<\/strong>: Nh\u00f3m nghi\u00ean c\u1ee9u c\u1ee7a Akero ph\u00e1t hi\u1ec7n ra r\u1eb1ng thu\u1ed1c c\u1ee7a h\u1ecd ho\u1ea1t \u0111\u1ed9ng hi\u1ec7u qu\u1ea3 \u0111\u1ebfn m\u1ee9c h\u1ecd ph\u1ea3i ph\u00e1t tri\u1ec3n c\u00e1c ti\u00eau chu\u1ea9n \u0111o l\u01b0\u1eddng m\u1edbi v\u00ec h\u1ec7 th\u1ed1ng \u0111\u00e1nh gi\u00e1 x\u01a1 gan hi\u1ec7n t\u1ea1i kh\u00f4ng th\u1ec3 ghi nh\u1eadn s\u1ef1 c\u1ea3i thi\u1ec7n r\u00f5 r\u1ec7t \u1edf b\u1ec7nh nh\u00e2n!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Akero Therapeutics: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2>\n<p>T\u00ednh \u0111\u1ebfn ng\u00e0y 25 th\u00e1ng 8 n\u0103m 2025, Akero Therapeutics, Inc. (AKRO) \u0111ang giao d\u1ecbch \u1edf m\u1ee9c <strong>49,23 USD<\/strong> tr\u00ean s\u00e0n NASDAQ. Nh\u01b0ng \u0111i\u1ec1u th\u1ef1c s\u1ef1 quan tr\u1ecdng &#8211; h\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o <strong>ng\u00e0y 7 th\u00e1ng 11 n\u0103m 2025<\/strong>. \u0110\u00f3 l\u00e0 ng\u00e0y Akero c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3, v\u00e0 theo l\u1ecbch s\u1eed, nh\u1eefng s\u1ef1 ki\u1ec7n n\u00e0y t\u1ea1o ra bi\u1ebfn \u0111\u1ed9ng gi\u00e1 l\u1edbn.<\/p>\n<h3>T\u1ea1i sao ng\u00e0y 7 th\u00e1ng 11 c\u00f3 th\u1ec3 thay \u0111\u1ed5i m\u1ecdi th\u1ee9<\/h3>\n<p>B\u00e1o c\u00e1o thu nh\u1eadp cu\u1ed1i c\u00f9ng v\u00e0o ng\u00e0y 8 th\u00e1ng 8 n\u0103m 2025 \u0111\u00e3 g\u00e2y ch\u1ea5n \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng. C\u00f4ng ty \u0111\u00e3 b\u00e1o c\u00e1o k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 2b SYMMETRY k\u00e9o d\u00e0i 96 tu\u1ea7n \u1ea5n t\u01b0\u1ee3ng \u0111\u01b0\u1ee3c c\u00f4ng b\u1ed1 tr\u00ean T\u1ea1p ch\u00ed Y h\u1ecdc New England, cho th\u1ea5y s\u1ef1 \u0111\u1ea3o ng\u01b0\u1ee3c c\u00f3 \u00fd ngh\u0129a th\u1ed1ng k\u00ea c\u1ee7a x\u01a1 gan b\u00f9 trong b\u1ec7nh nh\u00e2n MASH (<a href=\"https:\/\/www.stocktitan.net\/news\/AKRO\/akero-therapeutics-reports-second-quarter-2025-financial-results-and-2u5e2x076hoy.html\">K\u1ebft qu\u1ea3 T\u00e0i ch\u00ednh Qu\u00fd 2 2025<\/a>).<\/p>\n<p>Nh\u01b0ng s\u1ef1 ki\u1ec7n th\u1ef1c s\u1ef1 b\u00f9ng n\u1ed5 x\u1ea3y ra v\u00e0o <strong>ng\u00e0y 14 th\u00e1ng 8 n\u0103m 2025<\/strong> &#8211; \u0111\u00f3 l\u00e0 khi FDA ph\u00ea duy\u1ec7t efruxifermin (EFX) \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb MASH, t\u1ea1o ra c\u01a1 h\u1ed9i th\u1ecb tr\u01b0\u1eddng h\u01a1n 10 t\u1ef7 USD m\u00e0 ch\u01b0a c\u00f3 li\u1ec7u ph\u00e1p n\u00e0o t\u1ed3n t\u1ea1i (<a href=\"https:\/\/www.ainvest.com\/news\/akero-therapeutics-contrarian-opportunity-fda-approval-insider-selling-2508\/\">Ph\u00e2n t\u00edch Ph\u00ea duy\u1ec7t FDA<\/a>).<\/p>\n<p>\u0110\u00e2y l\u00e0 c\u00e1ch AKRO th\u01b0\u1eddng ph\u1ea3n \u1ee9ng v\u1edbi c\u00e1c tin t\u1ee9c l\u1edbn:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ng\u00e0y<\/th>\n<th>S\u1ef1 ki\u1ec7n<\/th>\n<th>Ph\u1ea3n \u1ee9ng Gi\u00e1<\/th>\n<th>Th\u1eddi gian<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>14 Th\u00e1ng 8, 2025<\/td>\n<td>Ph\u00ea duy\u1ec7t FDA<\/td>\n<td>+8% trong ng\u00e0y<\/td>\n<td>\u0110\u1ee3t t\u0103ng k\u00e9o d\u00e0i 2 ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>8 Th\u00e1ng 8, 2025<\/td>\n<td>B\u00e1o c\u00e1o Qu\u00fd 2<\/td>\n<td>T\u0103ng 12% trong tu\u1ea7n<\/td>\n<td>T\u0103ng tr\u01b0\u1edfng b\u1ec1n v\u1eefng<\/td>\n<\/tr>\n<tr>\n<td>7-10 Th\u00e1ng 5, 2025<\/td>\n<td>D\u1eef li\u1ec7u H\u1ed9i ngh\u1ecb EASL<\/td>\n<td>T\u0103ng 15% trong th\u00e1ng<\/td>\n<td>T\u0103ng d\u1ea7n \u0111\u1ec1u<\/td>\n<\/tr>\n<tr>\n<td>27 Th\u00e1ng 1, 2025<\/td>\n<td>\u0110\u1ec9nh cao l\u1ecbch s\u1eed<\/td>\n<td>\u0110\u1ec9nh 58,40 USD<\/td>\n<td>Thi\u1ebft l\u1eadp k\u1ef7 l\u1ee5c<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>M\u1eabu h\u00ecnh r\u00f5 r\u00e0ng: d\u1eef li\u1ec7u l\u00e2m s\u00e0ng t\u00edch c\u1ef1c v\u00e0 c\u00e1c c\u1ed9t m\u1ed1c ph\u00e1p l\u00fd th\u00fac \u0111\u1ea9y s\u1ef1 t\u0103ng gi\u00e1 \u0111\u00e1ng k\u1ec3, trong khi c\u00e1c b\u00e1o c\u00e1o thu nh\u1eadp cung c\u1ea5p \u0111\u1ed9ng l\u1ef1c b\u1ec1n v\u1eefng.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\ude80 H\u00e0nh Tr\u00ecnh Gi\u00e1 AKRO 6 Th\u00e1ng: T\u1eeb 35 USD \u0110\u1ebfn 49 USD<\/h2>\n<p>Th\u1eadt l\u00e0 m\u1ed9t h\u00e0nh tr\u00ecnh tuy\u1ec7t v\u1eddi! Trong s\u00e1u th\u00e1ng qua, AKRO \u0111\u00e3 mang l\u1ea1i <strong>l\u1ee3i nhu\u1eadn 40%<\/strong>, v\u01b0\u1ee3t tr\u1ed9i so v\u1edbi th\u1ecb tr\u01b0\u1eddng chung. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 ph\u00e2n t\u00edch chi ti\u1ebft:<\/p>\n<p><strong>Th\u00e1ng 2 n\u0103m 2025<\/strong>: C\u1ed5 phi\u1ebfu \u0111\u1ea1t \u0111\u1ec9nh cao l\u1ecbch s\u1eed 58,40 USD v\u00e0o ng\u00e0y 27 th\u00e1ng 1, sau \u0111\u00f3 \u0111i\u1ec1u ch\u1ec9nh quanh v\u00f9ng 52-55 USD khi nh\u00e0 \u0111\u1ea7u t\u01b0 ti\u00eau h\u00f3a \u0111\u00e0 t\u0103ng \u1ea5n t\u01b0\u1ee3ng.<\/p>\n<p><strong>Th\u00e1ng 3-4 n\u0103m 2025<\/strong>: Giao d\u1ecbch trong kho\u1ea3ng 48-52 USD khi th\u1ecb tr\u01b0\u1eddng ch\u1edd \u0111\u1ee3i d\u1eef li\u1ec7u quan tr\u1ecdng t\u1eeb H\u1ed9i ngh\u1ecb EASL v\u00e0o th\u00e1ng 5. \u0110\u00e2y l\u00e0 giai \u0111o\u1ea1n &#8220;b\u00ecnh y\u00ean tr\u01b0\u1edbc c\u01a1n b\u00e3o&#8221; \u0111i\u1ec3n h\u00ecnh.<\/p>\n<p><strong>Th\u00e1ng 5 n\u0103m 2025<\/strong>: H\u1ed9i ngh\u1ecb EASL t\u1eeb ng\u00e0y 7-10 th\u00e1ng 5 c\u00f4ng b\u1ed1 k\u1ebft qu\u1ea3 tu\u1ea7n 96 xu\u1ea5t s\u1eafc t\u1eeb th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 2b SYMMETRY. C\u1ed5 phi\u1ebfu t\u0103ng t\u1eeb 50 USD l\u00ean 54 USD trong v\u00e0i ng\u00e0y khi d\u1eef li\u1ec7u cho th\u1ea5y c\u1ea3i thi\u1ec7n x\u01a1 gan m\u00e0 kh\u00f4ng l\u00e0m n\u1eb7ng th\u00eam MASH.<\/p>\n<p><strong>Th\u00e1ng 6 n\u0103m 2025<\/strong>: Ph\u00ea duy\u1ec7t FDA v\u00e0o ng\u00e0y 28 th\u00e1ng 6 t\u1ea1o ra ch\u1ea5t x\u00fac t\u00e1c l\u1edbn th\u1ee9 hai, \u0111\u1ea9y c\u1ed5 phi\u1ebfu l\u00ean m\u1ee9c 56 USD. Vi\u1ec7c b\u00e1n n\u1ed9i b\u1ed9 tr\u1ecb gi\u00e1 44,7 tri\u1ec7u USD di\u1ec5n ra trong giai \u0111o\u1ea1n n\u00e0y, nh\u01b0ng \u0111\u01b0\u1ee3c hi\u1ec3u l\u00e0 ch\u1ed1t l\u1eddi thay v\u00ec m\u1ea5t ni\u1ec1m tin.<\/p>\n<p><strong>Th\u00e1ng 7-8 n\u0103m 2025<\/strong>: Giai \u0111o\u1ea1n \u0111i\u1ec1u ch\u1ec9nh sau ph\u00ea duy\u1ec7t \u0111\u01b0a c\u1ed5 phi\u1ebfu tr\u1edf l\u1ea1i m\u1ee9c hi\u1ec7n t\u1ea1i kho\u1ea3ng 49-50 USD, t\u1ea1o \u0111i\u1ec3m v\u00e0o h\u1ea5p d\u1eabn.<\/p>\n<p>H\u00ecnh \u1ea3nh k\u1ef9 thu\u1eadt v\u1eabn m\u1ea1nh m\u1ebd: AKRO \u0111ang giao d\u1ecbch tr\u00ean m\u1ee9c trung b\u00ecnh \u0111\u1ed9ng 200 ng\u00e0y l\u00e0 42,07 USD, v\u1edbi h\u1ed7 tr\u1ee3 v\u1eefng ch\u1eafc \u1edf m\u1ee9c 48 USD. RSI 14 ng\u00e0y \u1edf m\u1ee9c 54 cho th\u1ea5y kh\u00f4ng qu\u00e1 mua c\u0169ng kh\u00f4ng qu\u00e1 b\u00e1n &#8211; c\u00e2n b\u1eb1ng ho\u00e0n h\u1ea3o.<\/p>\n<h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2>\n<p>D\u1ef1a tr\u00ean \u0111\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u00e0 c\u00e1c c\u1ed9t m\u1ed1c l\u00e2m s\u00e0ng hi\u1ec7n t\u1ea1i, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec ch\u00fang t\u00f4i k\u1ef3 v\u1ecdng:<\/p>\n<ul>\n<li><strong>M\u1ee5c ti\u00eau cu\u1ed1i n\u0103m 2025<\/strong>: 65-70 USD (t\u0103ng 32-42%)<br \/> V\u1edbi b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 v\u00e0o ng\u00e0y 7 th\u00e1ng 11 v\u00e0 vi\u1ec7c tri\u1ec3n khai th\u01b0\u01a1ng m\u1ea1i EFX ti\u1ebfp t\u1ee5c, ch\u00fang t\u00f4i k\u1ef3 v\u1ecdng k\u1ebft th\u00fac n\u0103m m\u1ea1nh m\u1ebd.<\/li>\n<li><strong>D\u1ef1 b\u00e1o 2026<\/strong>: 85-95 USD (t\u0103ng 73-93%)<br \/> D\u1eef li\u1ec7u nghi\u00ean c\u1ee9u th\u1ef1c t\u1ebf SYNCHRONY giai \u0111o\u1ea1n 3 d\u1ef1 ki\u1ebfn trong n\u1eeda \u0111\u1ea7u n\u0103m 2026 c\u00f3 th\u1ec3 l\u00e0 ch\u1ea5t x\u00fac t\u00e1c l\u1edbn ti\u1ebfp theo.<\/li>\n<li><strong>D\u1ef1 b\u00e1o 2028<\/strong>: 120-140 USD (t\u0103ng 144-184%)<br \/> \u00c1p d\u1ee5ng th\u01b0\u01a1ng m\u1ea1i \u0111\u1ea7y \u0111\u1ee7 v\u00e0 kh\u1ea3 n\u0103ng m\u1edf r\u1ed9ng sang c\u00e1c ch\u1ec9 \u0111\u1ecbnh b\u1ec7nh gan kh\u00e1c.<\/li>\n<li><strong>T\u1ea7m nh\u00ecn d\u00e0i h\u1ea1n 2030<\/strong>: 180-220 USD (t\u0103ng 266-347%)<br \/> D\u1eabn \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng trong l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb MASH tr\u1ecb gi\u00e1 h\u01a1n 10 t\u1ef7 USD v\u1edbi ti\u1ec1m n\u0103ng tr\u1edf th\u00e0nh thu\u1ed1c blockbusters.<\/li>\n<\/ul>\n<p><strong>K\u1ebft lu\u1eadn<\/strong>: MUA M\u1ea0NH &#8211; T\u1ef7 l\u1ec7 r\u1ee7i ro-l\u1ee3i nhu\u1eadn \u1ee7ng h\u1ed9 ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 \u0111\u00e1ng k\u1ec3 nh\u1edd ph\u00ea duy\u1ec7t FDA v\u00e0 th\u1ecb tr\u01b0\u1eddng c\u00f3 th\u1ec3 ti\u1ebfp c\u1eadn r\u1ed9ng l\u1edbn.<\/p>\n<h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2>\n<h3>R\u1ee7i ro c\u1ea7n c\u00e2n nh\u1eafc<\/h3>\n<ul>\n<li><strong>Ph\u1ee5 thu\u1ed9c v\u00e0o th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/strong>: Gi\u00e1 tr\u1ecb c\u1ee7a AKRO ho\u00e0n to\u00e0n d\u1ef1a v\u00e0o th\u00e0nh c\u00f4ng c\u1ee7a th\u1eed nghi\u1ec7m giai \u0111o\u1ea1n 3. B\u1ea5t k\u1ef3 v\u1ea5n \u0111\u1ec1 an to\u00e0n ho\u1eb7c hi\u1ec7u qu\u1ea3 n\u00e0o c\u0169ng c\u00f3 th\u1ec3 l\u00e0m gi\u00e1 c\u1ed5 phi\u1ebfu s\u1ee5t gi\u1ea3m m\u1ea1nh.<\/li>\n<li><strong>Ti\u00eau ti\u1ec1n m\u1eb7t<\/strong>: M\u1eb7c d\u00f9 c\u00f3 v\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t 1,09 t\u1ef7 USD (<a href=\"https:\/\/www.stocktitan.net\/sec-filings\/AKRO\/10-q-akero-therapeutics-inc-quarterly-earnings-report-c361117b4692.html\">B\u00e1o c\u00e1o 10-Q Qu\u00fd 2 2025<\/a>), chi ph\u00ed ho\u1ea1t \u0111\u1ed9ng \u0111\u00e3 t\u0103ng 23% so v\u1edbi c\u00f9ng k\u1ef3 l\u00ean 80,9 tri\u1ec7u USD trong qu\u00fd v\u1eeba qua.<\/li>\n<li><strong>C\u1ea1nh tranh<\/strong>: Th\u1ecb tr\u01b0\u1eddng \u0111i\u1ec1u tr\u1ecb MASH ng\u00e0y c\u00e0ng \u0111\u00f4ng \u0111\u00fac v\u1edbi nhi\u1ec1u c\u00f4ng ty ph\u00e1t tri\u1ec3n li\u1ec7u ph\u00e1p.<\/li>\n<li><strong>Bi\u1ebfn \u0111\u1ed9ng<\/strong>: V\u1edbi ph\u1ea1m vi 52 tu\u1ea7n t\u1eeb 21,34 \u0111\u1ebfn 58,40 USD, AKRO c\u00f3 th\u1ec3 dao \u0111\u1ed9ng tr\u00ean 20% trong v\u00e0i tu\u1ea7n.<\/li>\n<\/ul>\n<h3>T\u00edn hi\u1ec7u t\u00edch c\u1ef1c cho n\u0103m 2025<\/h3>\n<ul>\n<li><strong>Ph\u00ea duy\u1ec7t FDA \u0111\u00e3 \u0111\u01b0\u1ee3c \u0111\u1ea3m b\u1ea3o<\/strong>: Ph\u00ea duy\u1ec7t mang t\u00ednh b\u01b0\u1edbc ngo\u1eb7t v\u00e0o ng\u00e0y 28 th\u00e1ng 6 n\u0103m 2025 t\u1ea1o ra ti\u1ec1m n\u0103ng doanh thu ngay l\u1eadp t\u1ee9c.<\/li>\n<li><strong>Th\u1ecb tr\u01b0\u1eddng h\u01a1n 10 t\u1ef7 USD<\/strong>: MASH \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn 17 tri\u1ec7u ng\u01b0\u1eddi M\u1ef9 v\u00e0 ch\u01b0a c\u00f3 ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb n\u00e0o &#8211; nhu c\u1ea7u r\u1ea5t l\u1edbn.<\/li>\n<li><strong>V\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t m\u1ea1nh<\/strong>: 1,09 t\u1ef7 USD cung c\u1ea5p ngu\u1ed3n l\u1ef1c \u0111\u1ebfn n\u0103m 2028, lo\u1ea1i b\u1ecf lo ng\u1ea1i pha lo\u00e3ng ng\u1eafn h\u1ea1n.<\/li>\n<li><strong>\u0110\u1ed3ng thu\u1eadn c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch<\/strong>: 7 nh\u00e0 ph\u00e2n t\u00edch duy tr\u00ec \u0111\u00e1nh gi\u00e1 &#8220;Mua M\u1ea1nh&#8221; v\u1edbi m\u1ee5c ti\u00eau trung b\u00ecnh 81,57 USD (t\u0103ng 65%).<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Nh\u00e0 giao d\u1ecbch m\u1edbi n\u00ean l\u00e0m g\u00ec h\u00f4m nay?<\/h2>\n<ol>\n<li><strong>B\u1eaft \u0111\u1ea7u nh\u1ecf<\/strong>: Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 5-10% danh m\u1ee5c \u0111\u1ea7u t\u01b0 v\u00e0o c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ee7i ro cao nh\u01b0 AKRO<\/li>\n<li><strong>Trung b\u00ecnh gi\u00e1<\/strong>: Thay v\u00ec mua m\u1ed9t l\u1ea7n, h\u00e3y mua theo t\u1eebng ph\u1ea7n trong v\u00e0i tu\u1ea7n<\/li>\n<li><strong>\u0110\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7<\/strong>: B\u1ea3o v\u1ec7 v\u1ed1n v\u1edbi m\u1ee9c d\u1eebng l\u1ed7 15-20% so v\u1edbi gi\u00e1 mua<\/li>\n<li><strong>Theo d\u00f5i ng\u00e0y 7 th\u00e1ng 11<\/strong>: B\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 c\u00f3 th\u1ec3 l\u00e0 ch\u1ea5t x\u00fac t\u00e1c l\u1edbn ti\u1ebfp theo<\/li>\n<\/ol>\n<p>G\u00f3c nh\u00ecn h\u00e0i h\u01b0\u1edbc: &#8220;Giao d\u1ecbch AKRO gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2 v\u1edbi m\u1ed9t nh\u00e0 khoa h\u1ecdc t\u00e0i ba &#8211; c\u1ef1c k\u1ef3 th\u00fa v\u1ecb nh\u01b0ng \u0111\u00f4i khi khi\u1ebfn b\u1ea1n h\u1ed3i h\u1ed9p. B\u00ed quy\u1ebft l\u00e0 bi\u1ebft khi n\u00e0o n\u00ean gi\u1eef v\u1eefng qua nh\u1eefng th\u0103ng tr\u1ea7m c\u1ea3m x\u00fac!&#8221;<\/p>\n<h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Akero Therapeutics, Inc. (AKRO) &#8211; T\u1eebng B\u01b0\u1edbc<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0111\u1ed9ng<\/th>\n<th>T\u1ea1i sao quan tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td>\n<td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p c\u1ed5 phi\u1ebfu NASDAQ v\u00e0 c\u00f3 ph\u00ed h\u1ee3p l\u00fd<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>M\u1edf v\u00e0 x\u00e1c minh t\u00e0i kho\u1ea3n<\/td>\n<td>Ho\u00e0n th\u00e0nh quy tr\u00ecnh KYC v\u1edbi x\u00e1c minh ID<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>N\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n<\/td>\n<td>Chuy\u1ec3n ti\u1ec1n qua chuy\u1ec3n kho\u1ea3n ng\u00e2n h\u00e0ng ho\u1eb7c c\u00e1c ph\u01b0\u01a1ng th\u1ee9c kh\u00e1c<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Nghi\u00ean c\u1ee9u k\u1ef9 AKRO<\/td>\n<td>Hi\u1ec3u r\u00f5 pipeline v\u00e0 r\u1ee7i ro c\u1ee7a c\u00f4ng ty<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0110\u1eb7t l\u1ec7nh gi\u1edbi h\u1ea1n<\/td>\n<td>\u0110\u1eb7t gi\u00e1 mua t\u1ed1i \u0111a \u0111\u1ec3 tr\u00e1nh tr\u1ea3 qu\u00e1 cao<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Gi\u00e1m s\u00e1t v\u1ecb th\u1ebf<\/td>\n<td>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c m\u1ee9c quan tr\u1ecdng<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u0110\u00e1nh gi\u00e1 \u0111\u1ecbnh k\u1ef3<\/td>\n<td>\u0110i\u1ec1u ch\u1ec9nh chi\u1ebfn l\u01b0\u1ee3c d\u1ef1a tr\u00ean c\u1eadp nh\u1eadt th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 T\u1ea1i sao Pocket Option ph\u00f9 h\u1ee3p v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0, Pocket Option mang l\u1ea1i nh\u1eefng l\u1ee3i th\u1ebf v\u01b0\u1ee3t tr\u1ed9i:<\/p>\n<ul>\n<li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u: 5 USD<\/strong> &#8211; \u0110\u00fang v\u1eady, b\u1ea1n kh\u00f4ng nh\u1ea7m \u0111\u00e2u! B\u1ea1n c\u00f3 th\u1ec3 b\u1eaft \u0111\u1ea7u ch\u1ec9 v\u1edbi n\u0103m \u0111\u00f4 la, r\u1ea5t ph\u00f9 h\u1ee3p \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c m\u00e0 kh\u00f4ng r\u1ee7i ro l\u1edbn.<\/li>\n<li><strong>Quy tr\u00ecnh KYC 1 ph\u00fat<\/strong> &#8211; T\u1ea3i l\u00ean b\u1ea5t k\u1ef3 gi\u1ea5y t\u1edd t\u00f9y th\u00e2n do ch\u00ednh ph\u1ee7 c\u1ea5p v\u00e0 b\u1ea1n s\u1eb5n s\u00e0ng giao d\u1ecbch trong v\u00e0i ph\u00fat, kh\u00f4ng ph\u1ea3i v\u00e0i ng\u00e0y.<\/li>\n<li><strong>H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> &#8211; T\u1eeb ti\u1ec1n \u0111i\u1ec7n t\u1eed \u0111\u1ebfn v\u00ed \u0111i\u1ec7n t\u1eed v\u00e0 th\u1ebb ng\u00e2n h\u00e0ng, b\u1ea1n c\u00f3 s\u1ef1 linh ho\u1ea1t tuy\u1ec7t v\u1eddi \u0111\u1ec3 ti\u1ebfp c\u1eadn l\u1ee3i nhu\u1eadn c\u1ee7a m\u00ecnh.<\/li>\n<\/ul>\n<p>Giao di\u1ec7n th\u00e2n thi\u1ec7n c\u1ee7a n\u1ec1n t\u1ea3ng gi\u00fap vi\u1ec7c ti\u1ebfp c\u1eadn c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ph\u1ee9c t\u1ea1p nh\u01b0 AKRO tr\u1edf n\u00ean d\u1ec5 d\u00e0ng h\u01a1n cho ng\u01b0\u1eddi m\u1edbi.<\/p>\n<h2>\ud83c\udf0d Akero Therapeutics n\u0103m 2025: C\u00e1ch m\u1ea1ng h\u00f3a \u0111i\u1ec1u tr\u1ecb gan<\/h2>\n<p>Akero Therapeutics kh\u00f4ng ch\u1ec9 l\u00e0 m\u1ed9t c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc th\u00f4ng th\u01b0\u1eddng &#8211; h\u1ecd \u0111ang ti\u00ean phong trong li\u1ec7u ph\u00e1p \u0111\u1ea7u ti\u00ean c\u00f3 th\u1ec3 th\u1ef1c s\u1ef1 \u0111\u1ea3o ng\u01b0\u1ee3c x\u01a1 gan do MASH g\u00e2y ra. Thu\u1ed1c ch\u1ee7 l\u1ef1c c\u1ee7a h\u1ecd, efruxifermin (EFX), \u0111\u1ea1i di\u1ec7n cho m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t trong l\u0129nh v\u1ef1c gan m\u1eadt h\u1ecdc.<\/p>\n<p>C\u00f4ng ty hi\u1ec7n \u0111ang chi\u1ebfm l\u0129nh cu\u1ed9c tr\u00f2 chuy\u1ec7n v\u1ec1 \u0111i\u1ec1u tr\u1ecb MASH v\u1edbi k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m SYMMETRY \u0111\u1ed9t ph\u00e1 cho th\u1ea5y 39% \u0111\u1ea3o ng\u01b0\u1ee3c x\u01a1 gan b\u00f9 &#8211; \u0111i\u1ec1u m\u00e0 tr\u01b0\u1edbc \u0111\u00e2y \u0111\u01b0\u1ee3c cho l\u00e0 kh\u00f4ng th\u1ec3.<\/p>\n<p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb n\u0103m 2025<\/strong>: Nh\u00f3m nghi\u00ean c\u1ee9u c\u1ee7a Akero ph\u00e1t hi\u1ec7n ra r\u1eb1ng thu\u1ed1c c\u1ee7a h\u1ecd ho\u1ea1t \u0111\u1ed9ng hi\u1ec7u qu\u1ea3 \u0111\u1ebfn m\u1ee9c h\u1ecd ph\u1ea3i ph\u00e1t tri\u1ec3n c\u00e1c ti\u00eau chu\u1ea9n \u0111o l\u01b0\u1eddng m\u1edbi v\u00ec h\u1ec7 th\u1ed1ng \u0111\u00e1nh gi\u00e1 x\u01a1 gan hi\u1ec7n t\u1ea1i kh\u00f4ng th\u1ec3 ghi nh\u1eadn s\u1ef1 c\u1ea3i thi\u1ec7n r\u00f5 r\u1ec7t \u1edf b\u1ec7nh nh\u00e2n!<\/p>\n"},"faq":[{"question":"Akero Therapeutics (AKRO) l\u00e0 c\u00f4ng ty g\u00ec?","answer":"Akero Therapeutics l\u00e0 m\u1ed9t c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc t\u1eadp trung v\u00e0o ph\u00e1t tri\u1ec3n li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb b\u1ec7nh gan, \u0111\u1eb7c bi\u1ec7t l\u00e0 b\u1ec7nh gan MASH, v\u1edbi thu\u1ed1c ch\u1ee7 l\u1ef1c efruxifermin (EFX)."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu AKRO?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu AKRO th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch ch\u1ee9ng kho\u00e1n cung c\u1ea5p c\u1ed5 phi\u1ebfu NASDAQ, b\u1eb1ng c\u00e1ch m\u1edf t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, nghi\u00ean c\u1ee9u k\u1ef9 v\u00e0 \u0111\u1eb7t l\u1ec7nh mua gi\u1edbi h\u1ea1n."},{"question":"R\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o AKRO l\u00e0 g\u00ec?","answer":"R\u1ee7i ro ch\u00ednh bao g\u1ed3m ph\u1ee5 thu\u1ed9c v\u00e0o k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng giai \u0111o\u1ea1n 3, chi ph\u00ed ho\u1ea1t \u0111\u1ed9ng cao, c\u1ea1nh tranh trong l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb MASH v\u00e0 bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu l\u1edbn."},{"question":"Ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng c\u1ee7a AKRO trong t\u01b0\u01a1ng lai ra sao?","answer":"D\u1ef1a tr\u00ean c\u00e1c c\u1ed9t m\u1ed1c l\u00e2m s\u00e0ng v\u00e0 ph\u00ea duy\u1ec7t FDA, AKRO c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 m\u1ea1nh v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 l\u00ean t\u1edbi 180-220 USD v\u00e0o n\u0103m 2030."},{"question":"Nh\u1eefng l\u1eddi khuy\u00ean n\u00e0o d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi khi mua AKRO?","answer":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 v\u1ed1n nh\u1ecf, \u00e1p d\u1ee5ng chi\u1ebfn l\u01b0\u1ee3c trung b\u00ecnh gi\u00e1, \u0111\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7 v\u00e0 theo d\u00f5i c\u00e1c s\u1ef1 ki\u1ec7n quan tr\u1ecdng nh\u01b0 b\u00e1o c\u00e1o thu nh\u1eadp \u0111\u1ec3 qu\u1ea3n l\u00fd r\u1ee7i ro hi\u1ec7u qu\u1ea3."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Akero Therapeutics (AKRO) l\u00e0 c\u00f4ng ty g\u00ec?","answer":"Akero Therapeutics l\u00e0 m\u1ed9t c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc t\u1eadp trung v\u00e0o ph\u00e1t tri\u1ec3n li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb b\u1ec7nh gan, \u0111\u1eb7c bi\u1ec7t l\u00e0 b\u1ec7nh gan MASH, v\u1edbi thu\u1ed1c ch\u1ee7 l\u1ef1c efruxifermin (EFX)."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu AKRO?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu AKRO th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch ch\u1ee9ng kho\u00e1n cung c\u1ea5p c\u1ed5 phi\u1ebfu NASDAQ, b\u1eb1ng c\u00e1ch m\u1edf t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, nghi\u00ean c\u1ee9u k\u1ef9 v\u00e0 \u0111\u1eb7t l\u1ec7nh mua gi\u1edbi h\u1ea1n."},{"question":"R\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o AKRO l\u00e0 g\u00ec?","answer":"R\u1ee7i ro ch\u00ednh bao g\u1ed3m ph\u1ee5 thu\u1ed9c v\u00e0o k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng giai \u0111o\u1ea1n 3, chi ph\u00ed ho\u1ea1t \u0111\u1ed9ng cao, c\u1ea1nh tranh trong l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb MASH v\u00e0 bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu l\u1edbn."},{"question":"Ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng c\u1ee7a AKRO trong t\u01b0\u01a1ng lai ra sao?","answer":"D\u1ef1a tr\u00ean c\u00e1c c\u1ed9t m\u1ed1c l\u00e2m s\u00e0ng v\u00e0 ph\u00ea duy\u1ec7t FDA, AKRO c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 m\u1ea1nh v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 l\u00ean t\u1edbi 180-220 USD v\u00e0o n\u0103m 2030."},{"question":"Nh\u1eefng l\u1eddi khuy\u00ean n\u00e0o d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi khi mua AKRO?","answer":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 v\u1ed1n nh\u1ecf, \u00e1p d\u1ee5ng chi\u1ebfn l\u01b0\u1ee3c trung b\u00ecnh gi\u00e1, \u0111\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7 v\u00e0 theo d\u00f5i c\u00e1c s\u1ef1 ki\u1ec7n quan tr\u1ecdng nh\u01b0 b\u00e1o c\u00e1o thu nh\u1eadp \u0111\u1ec3 qu\u1ea3n l\u00fd r\u1ee7i ro hi\u1ec7u qu\u1ea3."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T11:18:01+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)\",\"datePublished\":\"2025-08-25T11:18:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"datePublished\":\"2025-08-25T11:18:01+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T11:18:01+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)","datePublished":"2025-08-25T11:18:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","datePublished":"2025-08-25T11:18:01+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":347226,"slug":"how-to-buy-akero-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Akero Therapeutics, Inc. (AKRO) - Investimento em a\u00e7\u00f5es da Akero Therapeutics, Inc. (AKRO)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-akero-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/347229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=347229"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/347229\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334009"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=347229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=347229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=347229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}